Progression-Free Survival
Fig. 1 · Panel A
Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J Savage
Blood Cancer J 15(1) 129
ClinicalTrials.gov number: NCT01777152.
1 个 Figure · 3 个 KM 面板
Fig. 1. A+CHP provided a progression-free survival benefit over CHOP in patients with sALCL, including ALK+ and ALK– subgroups. Progression-free survival per investigator in patients with sALCL ( A ), and in the ALK+ ( B ) and ALK– ( C ) sALCL subgroups (intent-to-treat population, N = 316). A + CHP brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone, ALK anaplastic lymphoma kinase, CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, CI confidence interval, HR hazard ratio, PFS progression-free survival, sALCL systemic anaplastic large cell lymphoma.
Fig. 1 · Panel A
Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel B
Panel B 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 · Panel C
Panel C 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。